Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours

European Journal of Cancer

Volumn 44, Issue 13, 2008, Pages 1829-1834

  Cresta, S ^a   Sessa, C ^b   Catapano, C V ^b   Gallerani, E ^b   Passalacqua, D ^a   Rinaldi, A ^b   Bertoni, F ^b   Vigano L ^a   Maur, M ^b   Capri, G ^a   Maccioni, E ^c   Tosi, D ^a   Gianni, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c Southern Europe New Drug Organization SENDO   (Italy)

Author keywords

Bortezomib; Clinical study; Combination; Phase I; Proteasome inhibitor; Solid tumours; Taxane; Weekly paclitaxel

Indexed keywords

BORTEZOMIB; PACLITAXEL; TRANSCRIPTOME;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HEADACHE; HUMAN; INFECTION; MALE; MAXIMUM TOLERATED DOSE; MICROARRAY ANALYSIS; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPREGULATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; BREAST NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PROSTATIC NEOPLASMS; PYRAZINES; TREATMENT OUTCOME;

EID: 49549114644     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.05.022     Document Type: Article

References (9)

1. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I Trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20 (2002) 4420-4427
2. Aghajanian C., Soignet S., Dizon, Pien C.S., Adams J., and Elliott P.J. A Phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res 8 (2002) 2505-2511
3. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2108-2121
4. Haldar S., Baser A., and Croce C.M. Bcl 2 is the guardian of microtubule integrity. Cancer Res 57 (1997) 229-233
5. Nawrocki S.T., Sweeney-Gotsch B., Takamori R., and McCoukey D.J. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3 (2004) 59-70
6. Therasse P., Arbuck S., Eisenhauer E., et al. Response evaluation criteria in solid tumors (RECIST). J Nat Cancer Inst 92 (2000) 205
7. Lozza D., Rivino L., Guarda G., et al. The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4(+)IL-7R(hi) T cells. Eur J Immunol 38 (2008) 30-39
8. Dreicer R., Petrylak D., Agus D., Webb I., and Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13 (2007) 1208-1215
9. Lara Jr. P.N., Koczywas M., Quinn D.I., et al. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol 1 (2006) 126-134